During an MM&M webcast, Pfizer’s Bob Kristofco, MSW, said pharma “continues to have an expectation for more outcomes-oriented CME,” and that he expects grants from public and private sources will “begin to assess the current climate for [CPD].”
Sermo launched its HotSpots feature, which contextually links to learning opportunities based on discussions taking place in the online physician community.
Rep. Waxman leak unlikely to suppress off-label guidance
The chairman of the House Committee on Oversight and Government Reform provoked industry exponents last month by leaking FDA draft guidance on off-label journal reprints.
In an analyst call, Merck EVP and CFO Peter Kellogg said the company plans “continued DTC efforts for Singulair and Januvia as well as appropriate promotional support for Gardasil, RotaTeq and Zostavax,” along with support for the launch of Isentress and hopeful Cordaptive.
Mr. Mucus is going to work for Reckitt Benckiser, which bought Adams Respiratory Therapeutics, maker of the heavily advertised Mucinex franchise, for $2.3 billion.
With many of the industry’s major blockbuster drugs coming off-patent in the next few years, pharmaceutical companies are scrambling to extend the life of their biggest brands. Larry Friedman, PhD, offers some potential solutions based on brand architecture and flow of brand equity
European Commission gets negative feedback on public consultation
The European Commission drew fire from patient and public health advocacy groups for a public consultation on matters regarding regulation of the pharma industry.